The recent widespread availability and use of mechanical circulatory support is transforming
the management and outcomes of cardiogenic shock (CS). Clinical decision-making …

The earliest mention of the term cardiorenal syndrome (CRS) came about from a 2004
National Heart, Lung, and Blood Institute Working Group conference evaluating the …

Novel pharmacologic treatment options reduce mortality and morbidity in a cost‐effective
manner in patients with heart failure (HF). Undisputedly, the effective implementation of …

The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic
with primary respiratory manifestations in those who are symptomatic. It has spread to> 187 …

The use of mechanical circulatory support using percutaneous ventricular assist devices
(pVAD) has increased rapidly during the last decade without substantial new evidence for …

Acute myocardial infarction complicated by cardiogenic shock (AMICS) is a critical syndrome
with a high risk of morbidity and mortality. Current management consists of coronary …

Abstract Aims Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of
cardiovascular mediators. Its administration has been shown to be associated with impaired …

Cardiorenal syndrome (CRS) is a multi-organ disease characterized by the complex
interaction between heart and kidney during acute or chronic injury. The pathogenesis of …

In cardiorenal syndrome (CRS), heart failure and renal failure are pathophysiologically
closely intertwined by the reciprocal relationship between cardiac and renal injury. Type 1 …

Background Cardiogenic shock (CS) is caused by primary cardiac dysfunction and induced
by various and heterogeneous diseases (eg, acute impairment of cardiac performance, or …